MOLECULAR GENETIC INTERVENTION FOR AIDS--TRANSDOMINANT NEGATIVE FORM OF REV

艾滋病的分子遗传学干预--REV的跨显性阴性形式

• 批准号: 6297117
• 负责人: Gary J Nabel
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297117
• 关键词: AIDS therapy; HIV infections; blood treatment; cell transplantation; clinical research; clinical trials; gene therapy; helper T lymphocyte; human subject; human therapy evaluation; molecular genetics; polymerase chain reaction

In this study, we will evaluate the efficacy of intracellular inhibition of HIV infection with a mutant form of Rev, Rev M10. We propose to determine whether Rev M10 can improve the survival of T cells in humans. We plan to accomplish this by introducing the Rev M10 gene into the CD4+ T cells of HIV infected patients, ex vivo. These cells will then be returned to the patient, and their survival measured by PCR.

在本研究中，我们将评估 Rev M10 突变体对 HIV 感染的细胞内抑制功效。 我们建议确定 Rev M10 是否可以提高人类 T 细胞的存活率。 我们计划通过将 Rev M10 基因离体导入 HIV 感染患者的 CD4+ T 细胞中来实现这一目标。 然后这些细胞将被送回患者体内，并通过 PCR 测量它们的存活率。